| Literature DB >> 34495254 |
Paula Gobi Scudeller1, Mario Terra-Filho1, Orival Freitas Filho1, Filomena Regina Barbosa Gomes Galas2, Tiago Dutra de Andrade1, Daniela Odnicki Nicotari1, Laura Michelin Gobbo1, Fabio Antonio Gaiotto1, Ludhmila Abrahão Hajjar1, Fabio Biscegli Jatene1.
Abstract
OBJECTIVES: Pulmonary endarterectomy (PEA) is the gold standard treatment for chronic thromboembolic pulmonary hypertension (CTEPH). This study aimed at reporting outcomes of CTEPH patients undergoing PEA within 10 years, focusing on advances in anesthetic and surgical techniques.Entities:
Mesh:
Year: 2021 PMID: 34495254 PMCID: PMC8642817 DOI: 10.36416/1806-3756/e20200435
Source DB: PubMed Journal: J Bras Pneumol ISSN: 1806-3713 Impact factor: 2.624
Figure 1Study population stratified into groups according to time and advances in anesthetic and surgical techniques.
Description of advances implemented during the study period.
|
|
|
|
|---|---|---|
| Cardiopulmonary bypass | • Cooling duration at least 70 min (up to 15°C) | • Reduction by half of the total volume of the dilutional prime |
| • Rewarm duration at least 90 min (up to 36°C) | • Invasive blood pressure monitoring in the radial artery | |
| • Temperature control with tympanic thermometer | ||
| • Brain monitoring with BIS | ||
| • Cooling jacket of the head after anesthetic induction | ||
| Deep hypothermic circulatory arrest | • Each period to up to 20 min | • None |
| • Reperfusion of 10 min between each DHCA | ||
| Anesthetic procedure | • None | • Standardization of drugs in anesthetic induction |
| • Hemodynamic control of PH with dopamine and phenylephrine | ||
| • Femoral artery catheterization | ||
| • Zero fluid balance (avoiding positive balance) | ||
| • Use of transesophageal echocardiography | ||
| • Use of Cell Saver® | ||
| • Decrease in allogeneic transfusion | ||
| Surgical procedure | • None | • Cross-cannulation of the vena cava for the installation of CPB |
| • Installation of a cannula for drainage of cardiac cavities | ||
| • Use of thinner polypropylene yarns (6.0 and 7.0) for arteriorrhaphy | ||
| • Use of biological glue after arteriorrhaphy |
CPB: cardiopulmonary bypass; BIS: bispectral index; PH: pulmonary hypertension.
Postoperative outcomes.
|
|
|
|
|
|
|---|---|---|---|---|
|
| 5 (13.2%) | 3 (8.6%) | 5 (17.2%) | 0.674 |
|
| 7 (18.4%) | 2 (5.7%) | 4 (13.8%) | 0.497 |
|
| 13 (34.2%) | 11 (31.4%) | 3 (10.3%) |
|
| Bleeding | 12 (31.5%) | 9 (25.7%) | 3 (10.3%) |
|
| Pericardial effusion | 3 (7.8%) | 6 (17.1%) | 2 (6.9%) | 0.991 |
| Reoperation | 11 (29.0%) | 6 (17.1%) | 3 (10.3%) |
|
|
| 12 (31.6%) | 8 (22.9%) | 5 (17.2%) | 0.173 |
| Mediastinitis | 4 (10.5%) | 2 (5.7%) | 1 (3.5%) | 0.249 |
| Septic shock | 10 (26.3%) | 7 (20.0%) | 5 (17.2%) | 0.363 |
|
| 10 (26.3%) | 8 (22.8%) | 2 (6.9%) |
|
| Delirium | 6 (15.7%) | 8 (22.8%) | 2 (6.9%) | 0.384 |
| Stroke | 5 (13.2%) | 0 (0.0%) | 0 (0.0%) |
|
|
| 9 (23.6%) | 8 (22.9%) | 3 (10.3%) | 0.192 |
P value from the chi-square test (Mantel-Haenszel); p<0.05 was considered significant; n total number of patients.
Significant variables in the multivariate model for surgical and infectious complications and in-hospital mortality.
|
|
|
|
|---|---|---|
|
| ||
| Group | ||
| G1 | Reference | |
| G2 | 0.755 (0.250–2.275) | 0.574 |
| G3 | 0.221 (0.052–0.939) | 0.034 |
| Estimated PASP (mmHg) | 1.031 (1.007–1.056) | 0.012 |
|
| ||
| NYHA class | ||
| I/II | Reference | |
| III/IV | 3.538 (1.107–11.309) | 0.033 |
|
| ||
| Age (years) | 1.061 (1.018–1.105) | 0.047 |
| PVR (dyn.s.cm-5) | 1.002 (1.001–1.003) | 0.024 |
OR: odds ratio; PASP: pulmonary artery systolic pressure; NYHA: New York Heart Association; PVR: pulmonary vascular resistance; p<0.05 was considered significant; CI confidence interval.
Mid-term postoperative outcomes.
|
|
|
|
|
|
|---|---|---|---|---|
|
| 0.385 | |||
| I | 21 (75.0%) | 16 (61.5%) | 12 (63.1%) | |
| II | 6 (21.4%) | 9 (34.6%) | 6 (31.5%) | |
| III | 1 (3.5%) | 1 (3.8%) | 1 (5.2%) | |
|
| 28 ± 9.7 | 30.4 ± 8.4 | 30.6 ± 14.3 | 0.661 |
|
| 248.3 ± 99.3 | 301 ± 257.6 | 317.7 ± 265.2 | 0.518+ |
|
| 13 (50%) | 16 (72.7%) | 9 (50%) | 0.852* |
|
| 1 (3.4%) | 1 (3.8%) | 2 (9.5%) | 0.367* |
NYHA: New York Heart Association; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance.
P value from the chi-square test (Mantel-Haenszel);
P value from analysis of variance (ANOVA); n, patients with assessment; p<0.05 was considered significant.